T0	KEYPHRASE-NOTYPES 0 11	Conclusions
T1	KEYPHRASE-NOTYPES 22 27	study
T2	KEYPHRASE-NOTYPES 46 72	primary efficacy end point
T3	KEYPHRASE-NOTYPES 76 80	week
T4	KEYPHRASE-NOTYPES 88 109	ceftriaxone treatment
T5	KEYPHRASE-NOTYPES 130 141	improvement
T6	KEYPHRASE-NOTYPES 145 154	cognition
T7	KEYPHRASE-NOTYPES 188 208	physical functioning
T8	KEYPHRASE-NOTYPES 210 214	pain
T9	KEYPHRASE-NOTYPES 220 227	fatigue
T10	KEYPHRASE-NOTYPES 229 250	Clinical significance
T11	KEYPHRASE-NOTYPES 272 289	long-term effects
T12	KEYPHRASE-NOTYPES 308 326	long-term benefits
T13	KEYPHRASE-NOTYPES 335 352	ceftriaxone group
T14	KEYPHRASE-NOTYPES 356 376	physical functioning
T15	KEYPHRASE-NOTYPES 381 385	pain
T16	KEYPHRASE-NOTYPES 419 427	patients
T17	KEYPHRASE-NOTYPES 431 439	baseline
T18	KEYPHRASE-NOTYPES 474 491	troubling aspects
T19	KEYPHRASE-NOTYPES 495 521	posttreatment Lyme disease
T20	KEYPHRASE-NOTYPES 541 557	primary interest
T21	KEYPHRASE-NOTYPES 566 571	study
T22	KEYPHRASE-NOTYPES 579 588	cognition
T23	KEYPHRASE-NOTYPES 604 615	improvement
T24	KEYPHRASE-NOTYPES 637 641	week
T25	KEYPHRASE-NOTYPES 655 670	adverse effects
T26	KEYPHRASE-NOTYPES 688 699	ceftriaxone
T27	KEYPHRASE-NOTYPES 719 727	patients
T28	KEYPHRASE-NOTYPES 761 777	limited duration
T29	KEYPHRASE-NOTYPES 781 802	cognitive improvement
T30	KEYPHRASE-NOTYPES 811 816	risks
T31	KEYPHRASE-NOTYPES 821 826	weeks
T32	KEYPHRASE-NOTYPES 833 844	ceftriaxone
T33	KEYPHRASE-NOTYPES 857 862	weeks
T34	KEYPHRASE-NOTYPES 890 908	effective strategy
T35	KEYPHRASE-NOTYPES 913 944	sustained cognitive improvement
T36	KEYPHRASE-NOTYPES 955 972	certain subgroups
T37	KEYPHRASE-NOTYPES 974 982	patients
T38	KEYPHRASE-NOTYPES 1002 1026	neurologic abnormalities
T39	KEYPHRASE-NOTYPES 1043 1060	long-term benefit
T40	KEYPHRASE-NOTYPES 1066 1077	ceftriaxone
T41	KEYPHRASE-NOTYPES 1083 1101	predictor analyses
T42	KEYPHRASE-NOTYPES 1131 1141	hypothesis
T43	KEYPHRASE-NOTYPES 1167 1191	independent confirmation
T44	KEYPHRASE-NOTYPES 1201 1218	confirmation
T45	KEYPHRASE-NOTYPES 1220 1240	treatment strategies
